Activists slam Immunomedics’ $2B deal with Seattle Genetics in the middle of a proxy war
Immunomedics’ $2 billion deal with Seattle Genetics late last week provoked a fresh assault from a group of activist investors out to overthrow management …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
